BioCentury | Aug 15, 2018
Emerging Company Profile

Breaking bad biofilms

...Foundation. According to BioCentury’s BCIQ database, at least three other companies are developing biofilm-disrupting products. AlgiPharma A/S’s...
...shielding and that neither heparin nor NX-AS-401 would singly cover all three drivers of exacerbations. AlgiPharma...
...Shenda Baker Patents: 4 issued covering pulmonary applications of polycationic glycopolymers Companies and Institutions Mentioned AlgiPharma A/S...
Items per page:
1 - 1 of 1
BioCentury | Aug 15, 2018
Emerging Company Profile

Breaking bad biofilms

...Foundation. According to BioCentury’s BCIQ database, at least three other companies are developing biofilm-disrupting products. AlgiPharma A/S’s...
...shielding and that neither heparin nor NX-AS-401 would singly cover all three drivers of exacerbations. AlgiPharma...
...Shenda Baker Patents: 4 issued covering pulmonary applications of polycationic glycopolymers Companies and Institutions Mentioned AlgiPharma A/S...
Items per page:
1 - 1 of 1